White Papers
A new study reveals substantial efficiency gains
The pharmaceutical and biotechnology industries are at a crossroads. Escalating development costs, new modalities, increasing scientific and logistical demands, regulatory complexity, and mounting pressure to accelerate timelines are creating unprecedented challenges for drug developers.
Advancements in Biopharma: Enhancing Drug Development with Thermo Fisher Scientific’s qPCR Solutions
The biopharma industry is rapidly advancing, with the cell and gene therapy (CGT) market valued at $18 billion, including 27 approved gene therapies, 65 approved cell therapies, and 26 RNA therapies as of 2023.
Applications for qPCR in therapeutic monoclonal antibody development and manufacturing
Monoclonal antibodies are immunoglobulins produced in a laboratory setting that bind to specific antigens, such as epitopes expressed on the surfaces of cells. They can be used to treat various diseases, including some forms of cancer.
Updated requirements on balances for the pharmaceutical industry: Current status from USP, Ph.Eur., JP, ChP
This white paper summarizes what has changed with the latest revisions in the major global standards,United States Pharmacopeia (USP), European Pharmacopoeia (Ph.Eur.), Japanese Pharmacopoeia (JP), and Chinese Pharmacopoeia (ChP).
Accelerate Tox Material Delivery and Stay on Track for IND Submission
As development timelines tighten, generating toxicology (tox) data quickly has become a critical milestone on the path to IND submission.
Sterile Formulation Strategies to Shorten Timelines for First-in-Human Studies
On the long and costly path to market, early development decisions that prepare a molecule for its clinical journey are among the most critical.
Building a unified design-make-test-decide approach to drug discovery
Drug discovery has long followed a core loop: design a molecule, synthesize it, test its biological properties, and analyze the results to inform the next round of design.
Beyond algorithms: Building stronger AI foundations for drug discovery
Modern drug discovery produces more data than ever, from genomics and chemical screening to imaging and patient datasets
Leading the Way in Biotech Solutions Across JAPAC
Are you a U.S. biotech company struggling with patient recruitment, prolonged study timelines, rising costs, or unlocking the full value of your asset in key markets such as Japan or China
Quantifying the ROI of Integrated CDMO-CRO Models in Drug Development
As development costs climb and project timelines grow tighter, the traditional outsourcing model is showing its limitations.
